On December 16, 2022 Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, reported that its HER-Vaxx and CF33 technologies will feature at the upcoming ASCO (Free ASCO Whitepaper) Gastrointestinal Cancers Symposium, to be held in San Francisco on 19-21 January 2023 (Press release, Imugene, DEC 16, 2022, https://mcusercontent.com/e38c43331936a9627acb6427c/files/91374ce9-b26f-8daf-b534-ef57e1e78150/ASCO_GI_abstracts_ASX_ann_161222_29_.pdf [SID1234625329]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The 20th annual international event highlights the latest developments and breakthroughs in the field of gastrointestinal oncology, attended by more than 4,000 scientific figures, clinical researchers, academics, oncologists and medical practitioners from around the world. The abstract titles have been announced for the symposium, with Imugene to feature in the following:
Oral Abstract Session
• HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2-overexpressing metastatic or advanced gastric/GEJ adenocarcinoma— Overall survival analysis. View Source Trials in Progress Poster Session
• nextHERIZON: A phase 2 study of HER-Vaxx, a HER2-targeting peptide vaccine, in combination with chemotherapy or pembrolizumab in patients with HER2 metastatic or advanced gastric/gastroesophageal adenocarcinoma that progressed on or after trastuzumab treatment. View Source Poster Session
• Development of a novel chimeric oncolytic viral platform, CF33 and its derivatives, for peritonealdirected CF33-OV treatment of gastric cancer peritoneal carcinomatosis. View Source IMUGENE LIMITED ACN 009 179 551 2
• Ex vivo oncolytic and immune activity of CF33-hNIS-antiPDL1 against fresh peritoneal cells from patients with gastric cancer with and without peritoneal metastases. View Source